The Effect of Menopause and Menopausal Hormone Therapy on the Risk of Peripheral Artery Disease.
Panagiotis AnagnostisDimitri P MikhailidisAles BlincMojca JensterleMateja K JežovnikGerit-Holger SchernthanerPier Luigi AntignaniKatica Bajuk StudenMiso ŠabovićPavel PoredosPublished in: Current vascular pharmacology (2023)
Peripheral artery disease (PAD), defined as lower extremity arterial disease, constitutes an underestimated aspect of the menopause-associated risk of atherosclerotic cardiovascular disease (ASCVD). Accumulation of ASCVD risk factors, such as atherogenic dyslipidaemia, diabetes, and arterial hypertension, after the transition to menopause may contribute to atherosclerotic plaque formation in peripheral arteries. However, inconsistency exists among studies as to whether transition to menopause increases the risk of PAD, although early menopause (<45 years) or premature ovarian insufficiency may accelerate peripheral atherosclerotic plaque formation. Menopausal hormone therapy may decrease the risk of PAD if administered early (i.e., within the first 5-6 years after last menstruation), whereas it has no effect in women with established ASCVD.